- Travis, William D;
- Costabel, Ulrich;
- Hansell, David M;
- King, Talmadge E;
- Lynch, David A;
- Nicholson, Andrew G;
- Ryerson, Christopher J;
- Ryu, Jay H;
- Selman, Moisés;
- Wells, Athol U;
- Behr, Jurgen;
- Bouros, Demosthenes;
- Brown, Kevin K;
- Colby, Thomas V;
- Collard, Harold R;
- Cordeiro, Carlos Robalo;
- Cottin, Vincent;
- Crestani, Bruno;
- Drent, Marjolein;
- Dudden, Rosalind F;
- Egan, Jim;
- Flaherty, Kevin;
- Hogaboam, Cory;
- Inoue, Yoshikazu;
- Johkoh, Takeshi;
- Kim, Dong Soon;
- Kitaichi, Masanori;
- Loyd, James;
- Martinez, Fernando J;
- Myers, Jeffrey;
- Protzko, Shandra;
- Raghu, Ganesh;
- Richeldi, Luca;
- Sverzellati, Nicola;
- Swigris, Jeffrey;
- Valeyre, Dominique
Background
In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, and provided standardized terminology and diagnostic criteria. In addition, the historical "gold standard" of histologic diagnosis was replaced by a multidisciplinary approach. Since 2002 many publications have provided new information about IIPs.Purpose
The objective of this statement is to update the 2002 ATS/ERS classification of IIPs.Methods
An international multidisciplinary panel was formed and developed key questions that were addressed through a review of the literature published between 2000 and 2011.Results
Substantial progress has been made in IIPs since the previous classification. Nonspecific interstitial pneumonia is now better defined. Respiratory bronchiolitis-interstitial lung disease is now commonly diagnosed without surgical biopsy. The clinical course of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia is recognized to be heterogeneous. Acute exacerbation of IIPs is now well defined. A substantial percentage of patients with IIP are difficult to classify, often due to mixed patterns of lung injury. A classification based on observed disease behavior is proposed for patients who are difficult to classify or for entities with heterogeneity in clinical course. A group of rare entities, including pleuroparenchymal fibroelastosis and rare histologic patterns, is introduced. The rapidly evolving field of molecular markers is reviewed with the intent of promoting additional investigations that may help in determining diagnosis, and potentially prognosis and treatment.Conclusions
This update is a supplement to the previous 2002 IIP classification document. It outlines advances in the past decade and potential areas for future investigation.